Insight into the role of p62 in the cisplatin resistant mechanisms of ovarian cancer

Cisplatin is a platinum-based first-line drug for treating ovarian cancer. However, chemotherapy tolerance has limited the efficacy of cisplatin for ovarian cancer patients. Research has demonstrated that cisplatin causes changes in cell survival and death signaling pathways through its interaction...

Descripción completa

Detalles Bibliográficos
Autores principales: Yan, Xiao-Yu, Qu, Xian-Zhi, Xu, Long, Yu, Si-Hang, Tian, Rui, Zhong, Xin-Ru, Sun, Lian-Kun, Su, Jing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7164250/
https://www.ncbi.nlm.nih.gov/pubmed/32322174
http://dx.doi.org/10.1186/s12935-020-01196-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7164250/
https://www.ncbi.nlm.nih.gov/pubmed/32322174
http://dx.doi.org/10.1186/s12935-020-01196-w

Ejemplares similares